PSMA-1-DOTA Potentially for Effective Targeted Radioligand Therapy of Prostate Cancer
Open Access
- 2 September 2025
- journal article
- research article
- Published by Springer Nature in Molecular Imaging and Biology
- Vol. 27 (5) , 785-796
Abstract
Purpose: While PSMA-targeted radioligand therapy (RLT) has shown remarkable efficacy for treating end-stage prostate cancer, the α-emitting RLT often results in severe salivary gland toxicity, limiting its use. Various strategies to mitigate this side effect have been attempted with limited success. Accordingly, this study introduced a new PSMA-targeting ligand with more favorable binding characteristics than the existing ligands. Procedures: The binding affinity of PSMA-1-DOTA to PSMA was compared with that of PSMA-11 and PSMA I&T. Comparison of uptake in the salivary glands, kidneys and PC3pip tumor cells in the xenograft mouse models between [ 68 Ga]Ga-PSMA-1-DOTA, [ 68 Ga]Ga-PSMA-11 and [ 68 Ga]Ga-PSMA I&T was conducted with microPET/CT within the same week. The same mouse models were treated with [ 177 Lu]Lu-PSMA-1-DOTA or [ 177 Lu]Lu-PSMA-617. A compassionate use PET imaging study on a patient with metastatic castration-resistant prostate cancer was performed using [ 68 Ga]Ga-PSMA-1-DOTA. Results: The binding affinity of PSMA-1-DOTA to PSMA was found to be approximately four times greater than other PSMA-targeted ligands. Imaging with microPET/CT revealed significantly lower kidney, uptake and little salivary and lacrimal gland uptake with [ 68 Ga]Ga-PSMA-1-DOTA compared to other PSMA-radioligands. Preclinical efficacy studies demonstrated that [ 177 Lu]Lu-PSMA-1-DOTA inhibited tumor growth comparable to that with [ 177 Lu]Lu-PSMA-617, suggesting its potential to enhance the therapeutic window of targeted RLT by avoiding damage to the salivary glands. The compassionate use PET imaging confirmed the reduced salivary gland uptake of [ 68 Ga]Ga-PSMA-1-DOTA in the patient, indicating its potential utility as a targeting agent for RLT with α- or β-emitting radionuclides in patients with PSMA-positive prostate cancer. Conclusion: PSMA-1-DOTA shows reduced uptake in salivary glands while effectively targeting PSMA-expressing tumors, thus potentially avoiding the side effects of xerostomia, and possibly moving PSMA-targeted RLT to a more frontline therapy for prostate cancer rather than the current use as a last resort.Keywords
Funding Information
- National Cancer Institute (R01CA246678, R01CA260847, R01CA255925)
- DOD Peer Reviewed Cancer Research Program (W81XWH2210784)
This publication has 37 references indexed in Scilit:
- Salivary toxicity from PSMA-targeted radiopharmaceuticals: What we have learned and where we are goingCancer Treatment Reviews, 2024
- Response to RL‐225Ac in prostate cancer: Effect of prior treatment with RL‐177Lu: A systematic review of the literatureThe Prostate, 2023
- The salivary glands as a dose limiting organ of PSMA- targeted radionuclide therapy: A review of the lessons learnt so farNuclear Medicine and Biology, 2021
- A simple strategy to reduce the salivary gland and kidney uptake of PSMA-targeting small molecule radiopharmaceuticalsEuropean Journal of Nuclear Medicine and Molecular Imaging, 2021
- Dosimetry and safety of 177Lu PSMA-617 along with polyglutamate parotid gland protector: preliminary results in metastatic castration-resistant prostate cancer patientsEuropean Journal of Nuclear Medicine and Molecular Imaging, 2020
- Physiologic distribution of PSMA-ligand in salivary glands and seromucous glands of the head and neck on PET/CTOral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2018
- Injection of Botulinum Toxin for Preventing Salivary Gland Toxicity after PSMA Radioligand Therapy: an Empirical Proof of a Promising ConceptNuclear Medicine and Molecular Imaging, 2018
- Discovery of Orally Available Prodrugs of the Glutamate Carboxypeptidase II (GCPII) Inhibitor 2-Phosphonomethylpentanedioic Acid (2-PMPA)Journal of Medicinal Chemistry, 2016
- Radiation dosimetry and first therapy results with a 124I/131I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapyEuropean Journal of Nuclear Medicine and Molecular Imaging, 2014
- Regeneration of irradiated salivary glands with stem cell marker expressing cellsRadiotherapy and Oncology, 2011